Selective de‐implementation of routine in vivo dosimetry

• Published in: Journal of applied clinical medical physics Vol. 24; no. 7; pp. e13953 - n/a
• Main Authors: Mao, Serena P. H., Han‐Oh, Sarah, Moore, Joseph, Huang, Ellen, McNutt, Todd R., Souranis, Annette N., Briner, Valerie, Halthore, Aditya, Alcorn, Sarah R., Meyer, Jeffrey J., Viswanathan, Akila N., Wright, Jean L.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-07-2023; John Wiley and Sons Inc
• Subjects: Accreditation; Accuracy; de‐implementation; diode; Diodes; Dosimetry; Electrons; Humans; In Vivo Dosimetry; Patient safety; Physics; Planning; Quality improvement; Radiation Oncology Physics; Radiation therapy; Radiometry - methods; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted - methods; Radiotherapy, Conformal - methods; Skin; Tomography; Working groups; de-implementation; diode; in vivo dosimetry
• ISSN: 1526-9914; 1526-9914
• DOI: 10.1002/acm2.13953

As cone‐beam computed tomography (CBCT) has become the localization method for a majority of cases, the indications for diode‐based confirmation of accurate patient set‐up and treatment are now limited and must be balanced between proper resource allocation and optimizing efficiency without compromising safety. We undertook a de‐implementation quality improvement project to discontinue routine diode use in non‐intensity modulated radiotherapy (IMRT) cases in favor of tailored selection of scenarios where diodes may be useful. After analysis of safety reports from the last 5 years, literature review, and stakeholder discussions, our safety and quality (SAQ) committee introduced a recommendation to limit diode use to specific scenarios in which in vivo verification may add value to standard quality assurance (QA) processes. To assess changes in patterns of use, we reviewed diode use by clinical indication 4 months prior and after the implementation of the revised policy, which includes use of diodes for: 3D conformal photon fields set up without CBCT; total body irradiation (TBI); electron beams; cardiac devices within 10 cm of the treatment field; and unique scenarios on a case‐by‐case basis. We identified 4459 prescriptions and 1038 unique instances of diode use across five clinical sites from 5/2021 to 1/2022. After implementation of the revised policy, we observed an overall decrease in diode use from 32% to 13.2%, with a precipitous drop in 3D cases utilizing CBCT (from 23.2% to 4%), while maintaining diode utilization in the 5 selected scenarios including 100% of TBI and electron cases. By identifying specific indications for diode use and creating a user‐friendly platform for case selection, we have successfully de‐implemented routine diode use in favor of a selective process that identifies cases where the diode is important for patient safety. In doing so, we have streamlined patient care and decreased cost without compromising patient safety.